NCT03057145 - Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

February 25, 2020

Study Completion Date

June 9, 2021

Conditions

Solid Tumor

Interventions

DRUG

Prexasertib

LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer

DRUG

Olaparib

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.

Trial Locations (1)

Dana Farber Cancer Institute, Boston